IP Library Granted Patent US 9,060,931
Granted Patent B2
US 9,060,931 · App. 12/383,265 · Granted Jun 23, 2015

Compositions and methods for delivery of frozen particle adhesives

Inventors: Edward S. Boyden (Cambridge, MA); Daniel B. Cook (Seattle, WA); Roderick A. Hyde (Redmond, WA); Eric C. Leuthardt (St. Louis, MO); Nathan P. Myhrvold (Medina, WA); Elizabeth A. Sweeney (Seattle, WA); Lowell L. Wood, Jr. (Bellevue, WA)
Assignee: The Invention Science Fund I, LLC
A61K9/007A61K9/0019A61K9/08A61K9/1611A61K9/1641A61K9/1664A61K9/1688A61K9/19A61K31/00A61K31/337A61K31/70A61K31/7088A61K33/00A61K39/00A61K41/0004A61K45/06A61K51/1244
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,060,931
App. No.
12/383,265
Granted
Jun 23, 2015
Kind
B2
Abstract

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Claims (64)

1. A frozen particle composition, comprising:

one or more frozen particles approximately 500 microns or smaller in size; the one or more frozen particles including at least one of a pluripotent stem cell, a mesenchymal stem cell, a fibroblast, a keratinocyte, or a dermal progenitor cell;

at least one adhesive agent of one or more of fibrinogen, thrombin, bispecific protein, adhesion molecule, or an acrylic polymer or copolymer;

and at least one encapsulated therapeutic agent including at least one growth factor, antibiotic, or anesthetic.

2. The frozen particle composition of claim 1 , further including one or more of nitrogen, helium, neon, xenon, oxygen, air, krypton, chlorine, bromine, or argon.

3. The frozen particle composition of claim 1 , wherein the at least one adhesive agent is located in a compartment within the frozen particle.

4. The frozen particle composition of claim 1 , wherein the at least one adhesive agent is substantially in the form of a vesicle, caged compound, or other material that modulates the rate of diffusion or degradation of the at least one adhesive agent.

5. The frozen particle composition of claim 4 , wherein the at least one material reduces the rate of diffusion or degradation of the at least one adhesive agent.

6. The frozen particle composition of claim 1 , wherein the at least one adhesive agent includes at least one nontoxic, biocompatible, bioresorbable, or biodegradable agent.

7. The frozen particle composition of claim 1 , wherein the at least one adhesive agent is configured to form one or more of a hydrogen bond, ionic bond, covalent bond, or non-covalent bond with at least one substrate.

8. The frozen particle composition of claim 1 , wherein the at least one adhesive agent includes at least one crosslinking or derivatized agent.

9. The frozen particle composition of claim 8 , wherein the at least one adhesive agent is configured to form a crosslink bond with at least one component of at least one substrate.

10. The frozen particle composition of claim 9 , wherein the crosslink bond of the at least one adhesive agent is configured for modulation by one or more of a chemical agent, change in pH, change in exposure to air, vacuum, change in moisture content, change in pressure, or change in temperature.

11. The frozen particle composition of claim 9 , wherein the formation of a crosslink bond of the at least one adhesive agent is configured for modulation by exposure of the at least one adhesive agent to one or more of electromagnetic energy, optical energy, thermal energy, laser energy, ionizing radiation, non-ionizing radiation, or sonic energy.

12. The frozen particle composition of claim 1 , further including at least one therapeutic agent including at least one cytokine, hormone, vitamin, enzyme, epinephrine, or angiogenic factor.

13. The frozen particle composition of claim 1 , wherein the at least one adhesive agent includes a methacrylate.

14. The frozen particle composition of claim 13 , wherein the at least one adhesive agent includes at least one of poly(N,N-dimethyl-N-(ethoxycarbonylmethyl)-N-[2′-(methacryloyloxy)ethyl]-ammonium bromide) or poly(sulfobetaine methacrylate).

15. The frozen particle composition of claim 1 , further including one or more reinforcement agents including at least one of polyaramid, vinylester matrix, ceramic, fiberglass, cellulose, broad carbide, aromatic polyamide, nylon, silk, rayon, acetate, modacrylic, olefin, polyester, aromatic polyester, poly-lactic acid, vinyon, saran, spandex, vinalon, aromatic nylon, vinylidene chloride, modal, polybenzimidazole, sulfur, lyocell, orlon, zylon, high-performance polyethylene, polypyridobenzimidazole, vectran, acrylonitrile rubber, glass, copper, iron, steel, aluminum, magnesium, silicon, or silica.

16. The frozen particle composition of claim 1 , further including one or more abrasives including one or more of alluvium, sand, calcite, emergy, pumice, rouge, borazon, corundum, zirconia alumina, diamond, or novaculite.

17. The frozen particle composition of claim 1 , further including at least one of a nanoparticle, detection material, sensor, micro-syringe, or circuit.

18. The frozen particle composition of claim 1 , formulated to be administered by high velocity impact.

19. The frozen particle composition of claim 1 , further including one or more explosive materials including at least one of a carbonate, carbon dioxide, nitroglycerine, acid, base, epoxy, acrylamide polymer or copolymer, urethane, hypoxyapatite, or a reactive metal.

20. The frozen particle composition of claim 1 , wherein the at least one adhesive agent includes a detectable state that varies with its adhesive state.

21. The frozen particle composition of claim 1 , wherein the at least one adhesive agent further includes one or more epoxy adhesive, acrylic adhesive, urethane adhesive, polyurethane adhesive, silicone adhesive, cationic adhesive, anerobic adhesive, urethane acrylate, polyester acrylate, methyacrylate, or cyanoacrylate.

22. The frozen particle composition of claim 1 , wherein the at least one adhesive agent includes at least one α-cyanoacrylate and a fluorescent compound including at least one of a bis-benzoxazolyl compound, pyrylium salt, quantum dot, or coumarin compound.

23. The frozen particle composition of claim 1 , wherein the at least one adhesive agent includes an α-cyanoacrylate and 2,5-bis-(5-tert-butyl-2-benzoxasolyl)-thiophene.

24. The frozen particle composition of claim 1 , wherein the at least one adhesive agent further includes one or more of a base component, initiator component, or activator component.

25. The frozen particle composition of claim 1 , wherein the at least one adhesive agent further includes at least one curing component.

26. The frozen particle composition of claim 1 , wherein the at least one adhesive agent further includes at least one photopolymerizable adhesive, photocurable adhesive, thermal curable adhesive, free radical curable adhesive, or aerobic curable adhesive.

27. A method for providing at least one frozen particle composition to at least one substrate, comprising:

administering at least one frozen particle composition to at least one substrate,

wherein the at least one frozen particle composition includes one or more frozen particles approximately 500 microns or smaller in size; the one or more frozen particles including at least one of a pluripotent stem cell, a mesenchymal stem cell, a fibroblast, a keratinocyte, or a dermal progenitor cell;

at least one adhesive agent of one or more of fibrinogen, thrombin, bispecific protein, adhesion molecule, or an acrylic polymer or copolymer;

and at least one encapsulated therapeutic agent including at least one growth factor, antibiotic, or anesthetic.

28. The method of claim 27 , wherein the at least one frozen composition includes one or more of nitrogen, helium, neon, xenon, oxygen, air, krypton, chlorine, bromine, or argon.

29. The method of claim 27 , wherein the at least one adhesive agent includes at least one of a monomer, prepolymer, polymer, or copolymer.

30. The method of claim 29 , wherein the at least one adhesive agent includes at least one monomer of a self-polymerizing agent.

31. The method of claim 27 , wherein administering at least one frozen particle composition to at least one substrate includes accelerating, propelling, or ejecting the frozen particle composition toward the at least one substrate.

32. The method of claim 27 , wherein administering the at least one frozen particle composition to at least one substrate includes propelling, ejecting, or accelerating the at least one frozen particle composition toward the at least one substrate at a predetermined angle, predetermined velocity, or predetermined rate of administration.

33. The method of claim 27 , further including varying the rate, velocity, or angle at which the at least one frozen particle composition is administered to at least one substrate.

34. The method of claim 27 , further including administering to the at least one substrate at least one of a nanoparticle, detection material, sensor, micro-syringe, or circuit.

35. The method of claim 27 , wherein the at least one adhesive agent includes a detectable state that varies with its adhesive state.

36. The method of claim 35 , wherein the at least one adhesive agent includes one or more epoxy adhesive, acrylic adhesive, urethane adhesive, polyurethane adhesive, silicone adhesive, cationic adhesive, anerobic adhesive, urethane acrylate, polyester acrylate, methyacrylate, or cyanoacrylate.

37. The method of claim 35 , wherein the at least one adhesive agent includes at least one α-cyanoacrylate and a fluorescent compound including at least one of a bis-benzoxazolyl compound, pyrylium salt, quantum dot, or coumarin compound.

38. The method of claim 35 , wherein the at least one adhesive agent includes an α-cyanoacrylate and 2,5-bis-(5-tert-butyl-2-benzoxasolyl)-thiophene.

39. The method of claim 27 , wherein the at least one adhesive agent further includes one or more of a base component, initiator component, or activator component.

40. The method of claim 27 , wherein the at least one adhesive agent further includes at least one curing component.

41. The method of claim 27 , wherein the at least one adhesive agent includes at least one photopolymerizable adhesive, photocurable adhesive, thermal curable adhesive, free radical curable adhesive, or aerobic curable adhesive.

42. The method of claim 27 , wherein the adhesive agent includes at least one dye coinitiator.

43. The method of claim 27 , wherein the at least one adhesive agent includes one or more components that are inactive.

44. The method of claim 43 , wherein the one or more components are configured to be activated by administration.

45. The method of claim 27 , wherein the at least one adhesive agent includes two or more components configured to combine upon administration to at least one substrate.

46. A method of maintaining the approximation of tissue of at least one wound of a subject, comprising:

administering at least one frozen particle composition to at least one wound of a subject for a time sufficient to maintain the approximation of tissue of the at least one wound;

wherein the at least one frozen particle composition includes one or more frozen particles approximately 500 microns or smaller in size; the one or more frozen particles including at least one of a pluripotent stem cell, a mesenchymal stem cell, a fibroblast, a keratinocyte, or a dermal progenitor cell;

at least one adhesive agent of one or more of fibrinogen, thrombin, bispecific protein, adhesion molecule, or an acrylic polymer or copolymer;

and at least one encapsulated therapeutic agent including at least one growth factor, antibiotic, or anesthetic.

47. A frozen particle composition, comprising:

one or more frozen particles approximately 250 microns or smaller in size; the one or more frozen particles including at least one of a pluripotent stem cell, a mesenchymal stem cell, a fibroblast, a keratinocyte, or a dermal progenitor cell;

wherein the one or more frozen particles are coated by at least one adhesive agent of one or more of fibrinogen, thrombin, bispecific protein, adhesion molecule, or an acrylic polymer or copolymer.

48. A method for providing at least one frozen particle composition to at least one substrate, comprising:

administering at least one frozen particle composition to at least one substrate,

wherein the at least one frozen particle composition includes one or more frozen particles approximately 250 microns or smaller in size; the one or more frozen particles including at least one of a pluripotent stem cell, a mesenchymal stem cell, a fibroblast, a keratinocyte, or a dermal progenitor cell;

wherein the one or more frozen particles are coated by at least one adhesive agent of one or more of fibrinogen, thrombin, bispecific protein, adhesion molecule, or an acrylic polymer or copolymer.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2016
From: THE INVENTION SCIENCE FUND I LLC
To: GEARBOX, LLC
Reel/Frame 037607/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2015
From: SEARETE LLC
To: THE INVENTION SCIENCE FUND I, LLC
Reel/Frame 035567/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2009
From: BOYDEN, EDWARD S.; COOK, DANIEL B.; HYDE, RODERICK A.; LEUTHARDT, ERIC C.; MYHRVOLD, NATHAN P.; SWEENEY, ELIZABETH A.; WOOD, JR., LOWELL L.
To: SEARETE LLC
Reel/Frame 022969/0617 →
Continuity (19)
Continuation In Part 12290671 · Oct 31, 2008
Continuation In Part 12290683 · Oct 31, 2008
Continuation In Part 12290685 · Oct 31, 2008
Continuation In Part 12290686 · Oct 31, 2008
Continuation In Part 12290690 · Oct 31, 2008
Continuation In Part 12290691 · Oct 31, 2008
Continuation In Part 12290684 · Oct 31, 2008
Continuation In Part 12290670 · Oct 31, 2008
Continuation In Part 12290664 · Oct 31, 2008
Continuation In Part 12290659 · Oct 31, 2008
Continuation In Part 12290658 · Oct 31, 2008
Continuation In Part 12290665 · Oct 31, 2008
Continuation In Part 12290677 · Oct 31, 2008
Continuation In Part 12290687 · Oct 31, 2008
Continuation In Part 12290676 · Oct 31, 2008
Continuation In Part 12383264 · Mar 20, 2009
Continuation In Part 12383263 · Mar 20, 2009
Continuation In Part 12383260 · Mar 20, 2009
Related Publication 20100113615A1 · May 6, 2010